Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Radioimmunotherapy. Found 12 abstracts

Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Starodub AN, Lee FC, Gribbin TE, Richards DA, Lee M, Korn RL, Pandit-Taskar N, Goldsmith SJ, Intenzo CM, Sheikh A, Manzone TC, Horne H, Sharkey RM, Wegener WA, O'Reilly EM, Goldenberg DM, Von Hoff DD. Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. Eur J Cancer. 2015 Jul 14;51(14):1857-64.
Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE, Jenrette JM, Cohen SC, Black P, Brady LW. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg. 2010 Aug;113(2):192-8.   PMCID: not NIH funded
Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. European journal of pharmacology. 2009 Dec 25;625(1-3):41-54.   PMCID: PMC2783916
Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res. 2008 Feb;14(3):875-82.   PMCID: PMC2643368
Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.[see comment]. Cancer Research. 2004 Sep;64(17):6200-6.
Borghaei H, Schilder RJ. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Seminars in Nuclear Medicine. 2004 Jan;34(1 Suppl 1):4-9.
Borghaei H, Wallace SG, Schilder RJ. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma. Clinical Lymphoma. 2004 Oct;5 Suppl 1:S16-21.
von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annu Rev Med. 2003 Jan;54:343-69.
Adams GP, Weiner LM. Radioimmunotherapy of solid tumors: from fairytale to reality. Cancer Biother Radiopharm. 2001 Feb;16(1):9-11.
Adams GP, Shaller CC, Chappell LL, Wu C, Horak EM, Simmons HH, Litwin S, Marks JD, Weiner LM, Brechbiel MW. Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol. 2000 May;27(4):339-46.
Weiner LM, Adams GP. New approaches to antibody therapy. Oncogene. 2000 Dec 11;19(53):6144-51.
Weiner LM. Biological therapies for gastrointestinal cancers. Curr Opin Oncol. 1997 Jul;9(4):373-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Radioimmunotherapy

Radioimmunotherapy therapeutic use immunology Monoclonal Antibodies Human radiotherapy therapy Mice Neoplasms Male rt [Radiotherapy] Yttrium Radioisotopes Female Non-US Gov't Support Immunotherapy Animal Nude Mice erbB-2 Receptor US Gov't Support-PHS Iodine Radioisotopes 0 (Yttrium Radioisotopes) SCID Mice adverse effects Immunoglobulin Fragments Breast Neoplasms pd [Pharmacology] Tissue Distribution US Gov't Support-Non-PHS Treatment Outcome tu [Therapeutic Use] im [Immunology] ae [Adverse Effects] Immunotoxins Neoplasm Antibodies Non-Hodgkin Lymphoma methods Prospective Studies N' -N-N'-N''-N''-pentaacetic acid) 0 (ibritumomab tiuxetan) Yttrium-90 Combined Modality Therapy Epidermal Growth Factor Receptor Brain Neoplasms Bismuth CD20) 0 (Antigens me [Metabolism] 2-diamine (N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1 Chimeric Proteins Drug Design ri [Radionuclide Imaging] ad [Administration & Dosage] Heterologous Transplantation Prognosis Inbred ICR Mice Xenograft Model Antitumor Assays Gemcitabine agonists Alpha Particles 142434-84-2 Bispecific Antibodies derivatives Clivatuzumab tetraxetan Ovarian Neoplasms T-Lymphocytes Pancreatic cancer mt [Methods] Monoclonal) 0 (Antibodies Glioblastoma Carcinoembryonic Antigen 0 (Isothiocyanates) Alkylating Antineoplastic Agents administration & Kaplan-Meiers Estimate Dendritic Cells analogs & Passive Immunization Antibody Affinity Antibody pk [Pharmacokinetics] Antigen-Antibody Reactions 67-43-6 (Pentetic Acid) Neoplasm Antigens Toll-Like Receptors Adult Astatine Risk Factors erbB-2) EC 2-7-1-112 (Receptor Antibodies 0 (Immunoglobulin Variable Region) Middle Aged pharmacokinetics Gastrointestinal Neoplasms Multivariate Analysis Drug Delivery Systems diagnostic use Natural Killer Cells radionuclide imaging aa [Analogs & Derivatives] Isothiocyanates Non-US Gov't Research Support Aged Peptide Fragments Fluorine Radioisotopes Second Primary Neoplasms drug therapy Clinical Trials Immunoconjugates mortality Gene Therapy Molecular Weight Inbred BALB C Mice Pentetic Acid Experimental Neoplasms Radiopharmaceuticals Adjuvant Radiotherapy 0 (Immunotoxins) Immunoglobulin Variable Region Proportional Hazards Models Dacarbazine Antibody-Dependent Cell Cytotoxicity CD20 Antigens dosage Safety bi [Biosynthesis] Tumor Cell Line Young Adult Radioimmunodetection
Last updated on Thursday, June 04, 2020